These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

876 related items for PubMed ID: 30270071

  • 21. Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study.
    D'Erasmo L, Commodari D, Di Costanzo A, Minicocci I, Polito L, Ceci F, Montali A, Maranghi M, Arca M.
    Nutr Metab Cardiovasc Dis; 2020 Oct 30; 30(11):2027-2035. PubMed ID: 32830020
    [Abstract] [Full Text] [Related]

  • 22. Burden of familial heterozygous hypercholesterolemia in Uzbekistan: Time is muscle.
    Shek A, Alieva R, Kurbanov R, Hoshimov S, Nizamov U, Abdullaeva G, Nagay A.
    Atherosclerosis; 2018 Oct 30; 277():524-529. PubMed ID: 30270094
    [Abstract] [Full Text] [Related]

  • 23. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments.
    Rizos CV, Skoumas I, Rallidis L, Skalidis E, Tziomalos K, Garoufi A, Anagnostis P, Sfikas G, Kotsis V, Doumas M, Kolovou G, Lambadiari V, Dima I, Kiouri E, Zacharis E, Agapakis D, Attilakos A, Antza C, Vlachopoulos C, Liberopoulos EN.
    Int J Cardiol; 2021 Dec 15; 345():119-124. PubMed ID: 34687802
    [Abstract] [Full Text] [Related]

  • 24. PCSK9 inhibitors in clinical practice: Delivering on the promise?
    Stoekenbroek RM, Hartgers ML, Rutte R, de Wijer DD, Stroes ESG, Hovingh GK.
    Atherosclerosis; 2018 Mar 15; 270():205-210. PubMed ID: 29254691
    [Abstract] [Full Text] [Related]

  • 25. Latvian registry of familial hypercholesterolemia: The first report of three-year results.
    Latkovskis G, Saripo V, Gilis D, Nesterovics G, Upena-Roze A, Erglis A.
    Atherosclerosis; 2018 Oct 15; 277():347-354. PubMed ID: 30270070
    [Abstract] [Full Text] [Related]

  • 26. Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors.
    Razek O, Cermakova L, Armani H, Lee T, Francis GA, Mancini GBJ, Frohlich J, Brunham LR.
    Can J Cardiol; 2018 Aug 15; 34(8):1004-1009. PubMed ID: 30056842
    [Abstract] [Full Text] [Related]

  • 27. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS, Kennedy KF, Akeroyd JM, Morris PB, Bittner VA, Masoudi FA, Stone NJ, Petersen LA, Ballantyne CM.
    Circ Cardiovasc Qual Outcomes; 2018 May 15; 11(5):e004652. PubMed ID: 29748356
    [Abstract] [Full Text] [Related]

  • 28. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM, Rose LM, Kastelein JJP, Santos RD, Wei C, Revkin J, Yunis C, Tardif JC, Shear CL, Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators.
    J Clin Lipidol; 2018 May 15; 12(4):958-965. PubMed ID: 29685591
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).
    Rizos CV, Elisaf MS, Skoumas I, Tziomalos K, Kotsis V, Rallidis L, Garoufi A, Athyros VG, Skalidis E, Kolovou G, Koutagiar I, Papagianni M, Antza C, Katsiki N, Ganotakis E, Liberopoulos EN.
    Atherosclerosis; 2018 Oct 15; 277():308-313. PubMed ID: 30270064
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.
    Catapano AL, Pirillo A, Norata GD.
    Vasc Health Risk Manag; 2017 Oct 15; 13():343-351. PubMed ID: 28919772
    [Abstract] [Full Text] [Related]

  • 33. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
    Raal FJ, Hegele RA, Ruzza A, López JAG, Bhatia AK, Wu J, Wang H, Gaudet D, Wiegman A, Wang J, Santos RD.
    Arterioscler Thromb Vasc Biol; 2024 May 15; 44(5):1156-1164. PubMed ID: 38545781
    [Abstract] [Full Text] [Related]

  • 34. LDL cholesterol targets rarely achieved in familial hypercholesterolemia patients: A sex and gender-specific analysis.
    Schreuder MM, Hamkour S, Siegers KE, Holven KB, Johansen AK, van de Ree MA, Imholz B, Boersma E, Louters L, Bogsrud MP, Retterstøl K, Visseren FLJ, Roeters van Lennep JE, Koopal C.
    Atherosclerosis; 2023 Nov 15; 384():117117. PubMed ID: 37080805
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Attainment of LDL Cholesterol Treatment Goals in Children and Adolescents With Familial Hypercholesterolemia. The SAFEHEART Follow-up Registry.
    Saltijeral A, Pérez de Isla L, Alonso R, Muñiz O, Díaz-Díaz JL, Fuentes F, Mata N, de Andrés R, Díaz-Soto G, Pastor J, Pinilla JM, Zambón D, Pinto X, Badimón L, Mata P, SAFEHEART Investigators.
    Rev Esp Cardiol (Engl Ed); 2017 Jun 15; 70(6):444-450. PubMed ID: 27913073
    [Abstract] [Full Text] [Related]

  • 37. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
    Rallidis LS, Kiouri E, Katsimardos A, Kotakos C.
    Atherosclerosis; 2018 Aug 15; 275():262-264. PubMed ID: 29980053
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Novel treatment options for the management of heterozygous familial hypercholesterolemia.
    Polychronopoulos G, Tziomalos K.
    Expert Rev Clin Pharmacol; 2017 Dec 15; 10(12):1375-1381. PubMed ID: 28884604
    [Abstract] [Full Text] [Related]

  • 40. LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia.
    Bogsrud MP, Græsdal A, Johansen D, Langslet G, Hovland A, Arnesen KE, Mundal LJ, Retterstøl K, Wium C, Holven KB.
    J Clin Lipidol; 2019 Dec 15; 13(2):279-286. PubMed ID: 30910667
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 44.